glp-1 news nov 2025 drugs can be ‘too easy’ to get online, expert warns GLP-1 RA prescription trends: January

Ough, M

Because the treatment is affordable and patients will not have to take the time to recuperate or schedule additional sessions, the treatment is very accessible for potential patients

DPP-4 inhibitors are body weight neutral and they are generally tolerated well without side effects (see also corresponding section below) (12, 19, 21, 22)

Breaking News: Oral Wegovy 25mg Pill Set to Be Approved by End of 2025 Novo Nordisk Confirms FDA Submission for High-Dose Oral Wegovy (semaglutide) GLP-1 Receptor Agonist Novo Nordisk has confirmed it has submitted a high-dose version of its oral semaglutide (currently marketed for type 2 diabetes as the brand, Rybelsus) for FDA approval as a treatment for obesity, supported by strong clinical trials data where body mass index (BMI) was used as a key measure to evaluate body weight reduction and health improvements, with many participants having at least one weight related comorbidity, such as hypertension or dyslipidemia (a metabolic disorder characterized by abnormally high or low amounts of any or all lipids or lipoproteins in the blood)

We look forward to seeing you again and are happy to answer any questions you may have about the steps we take to keep you, and every patient, safe in our practice